CancerBESTNCT06851975
Research Into Biomarkers Predictive of Survival and Response to Cancer Treatment
An observational study of Cancer, run by Centre Antoine Lacassagne at 1 site in France.
Trial summary
Research into biomarkers predictive of survival and response to cancer treatment Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- blood sampling
- How many people
- 40,000 participants
- Where
- 1 siteFrance
- Study dates
- 7 Jan 2020to 31 Dec 2099
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with cancer receiving care at Centre Antoine Lacassagne are prospectively recruited for biospecimen collection during routine clinical blood sampling.
Who may be able to join
- Patient having a blood test, venous line insertion or injection on an implantable venous device scheduled as part of their standard care,
- Patient who has read the information note and stated that he/she has no objections
- Patient who has not objected to the use of this data for medical research purposes
- Patient with social security cover.
Who cannot join
- Patient already included in the study
- Patient considered to be a vulnerable person; vulnerable persons are defined in article L1121-5 to -8
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Centre Antoine Lacassagne
Nice, 0600
Victoria FERRARI, +33492031311, victoria.ferrari@nice.unicancer.fr
About this study
Research into biomarkers predictive of survival and response to cancer treatment
- Conditions
- Cancer
- Being tested
- blood sampling
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood samplingOther
36ml of blood will be taken during a blood sampling performed in standard practice
| Study group | Role | What they receive |
|---|---|---|
| principal | blood sampling Receives: Other: blood sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prediction
The aim of this project is to make a biobank in prevision of MR004 sub-projects which define specific biomarkers studied to identify biomarkers predictive of response.
Measured: day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2025
- Study start7 Jan 2020
- Primary completion31 Dec 2099 (estimated)
- Study completion31 Dec 2099 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 40,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Antoine Lacassagne
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06851975
- Sponsor's protocol ID
- 2018-61
- Acronym
- BEST
- Status last verified
- May 2026
- First submitted
- 14 Feb 2025
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: pseudonymised data will only be collected
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Research Into Biomarkers Predictive of Survival and Response to Cancer Treatment
- ClinicalTrials.gov ID
- NCT06851975
- Acronym / sponsor ID
- BEST / 2018-61
- Conditions
- Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40,000 participants (estimated)
- Lead sponsor
- Centre Antoine LacassagneUniversity, hospital or other
- Study start
- 7 Jan 2020 (actual)
- Primary completion
- 31 Dec 2099 (estimated)
- Study completion
- 31 Dec 2099 (estimated)
- First posted
- 28 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Research into biomarkers predictive of survival and response to cancer treatment
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| principal | – | Other: blood samplingblood sampling |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with cancer receiving care at Centre Antoine Lacassagne are prospectively recruited for biospecimen collection during routine clinical blood sampling.
Key inclusion criteria (4 listed)
- Patient having a blood test, venous line insertion or injection on an implantable venous device scheduled as part of their standard care,
- Patient who has read the information note and stated that he/she has no objections
- Patient who has not objected to the use of this data for medical research purposes
- Patient with social security cover.
Key exclusion criteria (2 listed)
- Patient already included in the study
- Patient considered to be a vulnerable person; vulnerable persons are defined in article L1121-5 to -8
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood sampling36ml of blood will be taken during a blood sampling performed in standard practice | Other | principal |
Primary outcome
Prediction
Time frame: day 1
The aim of this project is to make a biobank in prevision of MR004 sub-projects which define specific biomarkers studied to identify biomarkers predictive of response.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Individual participant dataSharing planned: Yes. pseudonymised data will only be collected
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Centre Antoine Lacassagne at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Victoria FERRARI, Dr (+33 492031311, victoria.ferrari@nice.unicancer.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prediction (time frame: day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.